CDH2 and neoplasm: In in vitro and raft cultures, Pal et al. found that fisetin treatment minimized tumor invasion and tumor cell migration of BRAF V600E mutation-positive melanoma cells and alleviated EMT by decreasing vimentin, Twist1, N-cadherin, Snail1, ZEB1, Slug, and fibronectin expression, and escalating E-cadherin levels [16].